HDBuzz

Huntington’s disease research news.

In plain language. Written by scientists.
For the global HD community.

Change Language
HDBuzz

Fund The Buzz

27%
$8,118 / $30,000 raised
Donate Now
  • Two Years In: New Long-Term Extension Data from PIVOT-HD for Votoplam

    Two Years In: New Long-Term Extension Data from PIVOT-HD for Votoplam

Latest News

HDBuzz Trial Tracker

Expected submission for regulatory approval of AMT-130 in the UK

uniQure
Expected: Q3 2026

Type B Meeting with FDA to Discuss Study Design Approaches for AMT-130

uniQure
Expected: Q2 2026

Sites for Phase 3 trial for votoplam, INVEST-HD, now open. Updates on recruitment and first dosing imminent.

Novartis/PTC Therapeutics
Expected: Spring 2026

Phase 3 for SOM3355 to commence

SOM Biotech
Expected: Q4 2026

GENERATION-HD2 Trial Expected to Complete

Roche
Expected: 2026

Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02

Alnylam Pharmaceuticals
Expected: 2026

Update on Planned Phase 2/3 Study for WVE-003

Wave Life Sciences
Expected: Not disclosed

Update on Phase 1/2a Clinical Data of VO659

Vico Therapeutics
Expected: Not disclosed

First participant in Phase 1/2 gene therapy trial dosed

Roche
Expected: Not disclosed

First participant dosed in POINT-HD trial

Roche
Expected: Not disclosed

Updates from the ongoing placebo-controlled Phase 2/3 FALCON-HD trial

Skyhawk Therapeutics
Expected: Not disclosed

Previously featured

More…

Start here

New to HD Research? Click here to get an overview

Follow HDBuzz

Sign up to our monthly email summary by entering your email address on our mailing list page.

Suggest an article

Is there something you want us to write about? Tell us about it here. We consider all suggestions but can’t promise to write content about any particular suggestion.

Email editors@hdbuzz.net